
News|Videos|November 11, 2022
Cross Q&A: Team Dana-Farber
The Memorial Sloan Kettering team gets their chance to question the Dana-Farber team on the datasets they presented.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
2
Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup
3
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
4
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
5






















































































